Lexicon Pharmaceuticals, Inc.
LXRX
$2.32
-$0.02-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -61.12M | -26.09M | -50.34M | -68.58M | -120.62M |
| Total Depreciation and Amortization | 481.00K | 555.00K | 621.00K | 628.00K | 603.00K |
| Total Amortization of Deferred Charges | 2.11M | 1.98M | 1.70M | 1.61M | 1.61M |
| Total Other Non-Cash Items | 14.30M | 8.82M | 7.06M | 4.81M | 3.09M |
| Change in Net Operating Assets | -20.76M | -24.07M | -26.89M | -10.58M | 13.42M |
| Cash from Operations | -64.99M | -38.80M | -67.85M | -72.11M | -101.90M |
| Capital Expenditure | -- | -- | -- | -474.00K | -781.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -29.77M | 2.18M | 113.02M | 162.36M | 164.02M |
| Cash from Investing | -29.77M | 2.18M | 113.02M | 161.89M | 163.23M |
| Total Debt Issued | 55.00M | -- | -- | -- | -- |
| Total Debt Repaid | -62.26M | -53.00M | -48.00M | -45.00M | -45.00M |
| Issuance of Common Stock | 71.15M | 70.12M | 73.00K | -- | 0.00 |
| Repurchase of Common Stock | -2.84M | -2.84M | -572.00K | -597.00K | -597.00K |
| Issuance of Preferred Stock | 26.55M | 26.55M | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -78.00K | -88.00K |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.27M | -- | -- | -1.00K | -907.00K |
| Cash from Financing | 85.32M | 40.83M | -48.50M | -45.68M | -46.59M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.44M | 4.20M | -3.33M | 44.11M | 14.75M |